Document is current
Any future updates will be listed below
-
Authors
Ramineni, Varsha https://orcid.org/0000-0002-0330-3184
Millroth, Philip
Iyadurai, Lalitha
Jaki, Thomas https://orcid.org/0000-0002-1096-188X
Kingslake, Jonathan https://orcid.org/0000-0003-1741-1802
Highfield, Julie
Summers, Charlotte https://orcid.org/0000-0002-7269-2873
Bonsall, Michael B. https://orcid.org/0000-0003-0250-0423
Holmes, Emily A. https://orcid.org/0000-0001-7319-3112
-
Funding
Funding for this research was provided by:
Wellcome Trust (223016/Z/21/Z, 223016/Z/21/Z, 223016/Z/21/Z, 223016/Z/21/Z, 223016/Z/21/Z, 223016/Z/21/Z, 223016/Z/21/Z, 223016/Z/21/Z, 223016/Z/21/Z)
- License Information
-
More Information
Article History
Received: 29 September 2022
Revised: 24 March 2023
Accepted: 28 March 2023
First Online: 26 April 2023
Competing interests
: The study was funded by the Wellcome Trust (223016/Z/21/Z). JK is shareholder and director of P1vital Products Ltd which is the study sponsor and manufacturer of i-spero®. VR and LI are employed by P1vital Products Ltd. MBB is an adjunct member of the DMC. CS salary is partly funded by National Institute for Health Research (NIHR133788) and Medical Research Council (MR/S035753/1 and MR/X005070/1). TJ is supported by a grant from UK Medical Research Council (MC_UU_00002/14). EAH salary is part funded by Wellcome Trust (223016/Z/21/Z) via consultancy to P1vital Products Ltd. EAH is on the Board of Trustees of the MQ Foundation. EAH also receives funding from the Swedish Research Council, Rannís The Icelandic Research Fund, OAK foundation, The Lupina Foundation and AFA Försäkring. EAH developed the intervention approach and training in using it (Anenome™). EAH receives book royalties from Guildford Press and Oxford University Press, and receives occasional honoraria for conference keynotes and clinical workshops. All other authors declare no competing interests.
